Last reviewed · How we verify
Fibroblasts and keratinocytes
This is a cellular therapy product consisting of cultured fibroblasts and keratinocytes that promote tissue regeneration and wound healing.
This is a cellular therapy product consisting of cultured fibroblasts and keratinocytes that promote tissue regeneration and wound healing. Used for Wound healing and tissue regeneration, Burn injuries, Chronic wounds.
At a glance
| Generic name | Fibroblasts and keratinocytes |
|---|---|
| Sponsor | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus |
| Drug class | Cell therapy |
| Modality | Biologic |
| Therapeutic area | Regenerative Medicine / Dermatology |
| Phase | FDA-approved |
Mechanism of action
Fibroblasts and keratinocytes are primary cell types involved in skin and tissue repair. When cultured and applied therapeutically, they secrete growth factors and extracellular matrix components that stimulate angiogenesis, collagen deposition, and epithelialization. This cellular approach aims to restore damaged or deficient tissue through biological regeneration rather than pharmacological mechanisms.
Approved indications
- Wound healing and tissue regeneration
- Burn injuries
- Chronic wounds
Common side effects
- Infection at application site
- Immune reaction
- Graft rejection
Key clinical trials
- Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) (PHASE1, PHASE2)
- Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease (PHASE1, PHASE2)
- Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy (PHASE1, PHASE2)
- Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant (PHASE1)
- Expanded Access Program Evaluating SkinTE in the Treatment of Wagner 1 Diabetic Foot Ulcers
- Topical Hyaluronic Acid Adjunctive Effects on Healing After Free Gingival Grafting in Smokers and Non-Smokers
- SkinTE® for the Treatment of Wagner 1 Diabetic Foot Ulcers (COVER DFUS II) (PHASE3)
- 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: